Johnson & Johnson reported first-quarter results on Tuesday that exceeded Wall Street expectations and raised its full-year forecast, driven by strong demand for key treatments including Darzalex and Tremfya, which helped offset a sharp decline in sales of its blockbuster autoimmune drug Stelara.
14 Apr 2026-14:32
14 Apr 2026-14:32
